Related Experiment Video
Updated: Feb 7, 2026
13:22
Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
Published on: October 23, 2019
8.3K
Ibrutinib.
Andriani Charalambous1, Mark-Alexander Schwarzbich2,3, Mathias Witzens-Harig4
1School of Medicine and Dentistry, Queen Mary University of London, London, UK.
Summary
Ibrutinib, a Bruton
Area of Science:
- Oncology
- Pharmacology
- Immunology
Background:
- Abnormal B-cell receptor (BCR) signaling drives B-cell malignancy progression.
- Bruton's tyrosine kinase (BTK) is crucial for BCR signaling.
- Ibrutinib is a potent, selective, irreversible BTK inhibitor.
Purpose of the Study:
- To review the structure, mechanism of action, and toxicities of Ibrutinib.
- To present preclinical and clinical data on Ibrutinib efficacy and resistance.
- To explore Ibrutinib's role in modulating the tumor microenvironment and combination strategies.
Main Methods:
- Review of existing preclinical and clinical data on Ibrutinib.
- Analysis of Ibrutinib's mechanism of action, including BTK inhibition.
- Discussion of emerging resistance mechanisms and therapeutic strategies.
Main Results:
- Ibrutinib is approved for several B-cell malignancies and shows promise in others.
- It offers treatment options for relapsed/refractory patients and those insensitive to chemotherapy.
- Ibrutinib demonstrates a favorable risk profile, suitable for less fit patients.
- Emerging resistance necessitates further investigation into mechanisms and overcoming strategies.
- Ibrutinib modulates the tumor microenvironment, suggesting broader applications.
Conclusions:
- Ibrutinib is an effective targeted therapy for B-cell malignancies, offering new treatment avenues.
- Understanding and overcoming Ibrutinib resistance is critical for sustained patient benefit.
- Combination strategies, particularly with immunotherapy, hold significant therapeutic potential.
